The first drug approved for moderate-to-severe OSA in this population — and a route to coverage that a BMI threshold does not open.
FDA approved Zepbound for moderate-to-severe obstructive sleep apnoea in adults with obesity in December 2024, on the strength of SURMOUNT-OSA, which showed large reductions in apnoea-hypopnoea index at 52 weeks both with and without CPAP.
For coverage this is more consequential than it looks. A documented OSA diagnosis is a discrete medical condition with an approved indication, which is a materially stronger prior-authorisation argument than a BMI threshold plus a comorbidity.
If you have suspected sleep apnoea and are paying cash for tirzepatide, a sleep study is the highest-value thing you can do about your bill.
It does not replace CPAP by default. Reduction in AHI is not the same as resolution, and that decision belongs to the clinician managing your sleep medicine, ideally after a repeat study.
Sources
- SURMOUNT-OSA, NCT05412004 — source
- FDA approval announcement, December 2024
Dated 2024-12-20. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.